Denali Therapeutics Inc
NASDAQ:DNLI

Watchlist Manager
Denali Therapeutics Inc Logo
Denali Therapeutics Inc
NASDAQ:DNLI
Watchlist
Price: 14.89 USD -6.65% Market Closed
Market Cap: 2.1B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one DNLI stock under the Base Case scenario is 16.81 USD. Compared to the current market price of 14.89 USD, Denali Therapeutics Inc is Undervalued by 11%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DNLI Relative Value
Base Case
16.81 USD
Undervaluation 11%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
44
Median 3Y
30.7
Median 5Y
30.7
Industry
7.4
Forward
241.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-12.6
Median 5Y
-11.4
Industry
21.6
Forward
-5.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-11.4
Median 5Y
-10.7
Industry
19.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-10.3
Median 5Y
-10
Industry
23.9
More Details
1.6
P/B
P/B
Price to Book Value
1.6
vs History
93
vs Industry
41
Median 3Y
3.1
Median 5Y
4.1
Industry
2.4
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
46
Median 3Y
18.3
Median 5Y
21.9
Industry
7.7
Forward
147.7
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-8.2
Median 5Y
-7.4
Industry
3.9
Forward
-2.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-7.9
Median 5Y
-7.2
Industry
3.6
Forward
-2.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-8.4
Median 5Y
-8
Industry
4.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-8.1
Median 5Y
-7.5
Industry
3.2
More Details
2.2
EV/IC
EV/IC
Enterprise Value to IC
2.2
vs History
95
vs Industry
38
Median 3Y
11.2
Median 5Y
13.7
Industry
4.5
More Details

Multiples Across Competitors

DNLI Competitors Multiples
Denali Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Denali Therapeutics Inc
NASDAQ:DNLI
2.1B USD 0 -5 -2.6 -2.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 539 777.2 -173 668.1 -210 888.4 -208 482
US
Abbvie Inc
NYSE:ABBV
373.4B USD 6.6 88.1 17.2 26
US
Amgen Inc
NASDAQ:AMGN
167.9B USD 5 41 16.5 29.3
US
Gilead Sciences Inc
NASDAQ:GILD
140.2B USD 4.9 292.2 11.4 14.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.2B USD 11.7 -241.3 26.4 27.7
US
Epizyme Inc
F:EPE
94.1B EUR 1 928 -492 -535.7 -521.5
AU
CSL Ltd
ASX:CSL
121.2B AUD 5 27.7 17.1 21.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
74.6B USD 5.3 16.9 11.2 12.5
US
Seagen Inc
F:SGT
39.3B EUR 18.6 -56.9 -61.3 -55.3
NL
argenx SE
XBRU:ARGX
32B EUR 15.9 41.8 306.7 -2 259.2
P/S Multiple
Revenue Growth P/S to Growth
US
Denali Therapeutics Inc
NASDAQ:DNLI
Average P/S: 3 654 177.8
Not Available
-22%
N/A
FR
Pharnext SCA
OTC:PNEXF
36 539 777.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
5
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
E
Epizyme Inc
F:EPE
1 928
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.3
7%
0.8
US
S
Seagen Inc
F:SGT
18.6
30%
0.6
NL
argenx SE
XBRU:ARGX
15.9
37%
0.4
P/E Multiple
Earnings Growth PEG
US
Denali Therapeutics Inc
NASDAQ:DNLI
Average P/E: 84.6
Negative Multiple: -5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -173 668.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88.1
88%
1
US
Amgen Inc
NASDAQ:AMGN
41
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
292.2
185%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -492 N/A N/A
AU
CSL Ltd
ASX:CSL
27.7
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A N/A
NL
argenx SE
XBRU:ARGX
41.8
19%
2.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Denali Therapeutics Inc
NASDAQ:DNLI
Average EV/EBITDA: 58.1
Negative Multiple: -2.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 888.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.2
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.5
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
11.4
6%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.4
16%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -535.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
12%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.2
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.3 N/A N/A
NL
argenx SE
XBRU:ARGX
306.7
168%
1.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Denali Therapeutics Inc
NASDAQ:DNLI
Average EV/EBIT: 21.9
Negative Multiple: -2.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 482 N/A N/A
US
Abbvie Inc
NYSE:ABBV
26
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.3
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.3
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.7
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.5 N/A N/A
AU
CSL Ltd
ASX:CSL
21.4
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.3 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 259.2 N/A N/A

See Also

Summary
DNLI intrinsic value, competitors valuation, and company profile.
DCF Valuation
DNLI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DNLI stock valuation using valuation multiples.
Wall Street Estimates
DNLI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DNLI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 238,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.